Figure 5

Breast-cancer-specific survival (BCSS) according to serum HER2 ECD level. (A) BCSS according to serum HER2 ECD level [elevated (>15.2 ng/ml) vs normal (≤15.2 ng/ml)] in the overall series (B–F) Subgroup analyses by tumor size (B), LN status (C), hormone-receptor status (D), tissue HER2 status (E), and anti-HER2 therapy (F). (A–F) No adjusted HRs in each subgroup were found to be independently significant, except in the subgroup with positive tissue HER2 status (adjusted HR = 2.6, 95% CI = 1.2–5.3) and nontrastuzumab (adjusted HR = 8.2, 95% CI = 1.7–40.8). All HRs were adjusted according to the following eight variables: tumor size, LN status, tumor grade, lymphovascular invasion, tissue HER2 status, chemotherapy, antihormone therapy, and trastuzumab therapy.